278eP Real-world experience with tebentafusp in metastatic uveal melanoma: Preliminary efficacy and toxicity results from a single-center cohort

ESMO rare cancers. 2026 Open access

Read full text
Authors: D. Vidal Jiménez, P. Capdevila Gaudens, A. Ortiz Gracia, Roberto Díaz Beveridge
DOI: 10.1016/j.esmorc.2026.100483
Cited by: 0

Abstract

Metastatic uveal melanoma is a rare and aggressive disease with limited systemic treatment options. Tebentafusp, a bispecific fusion protein (TCR-anti-CD3) targeting gp100 presented by HLA-A*02:01, has shown significant overall survival (OS) benefit in the IMCgp100-202 phase III trial, despite a low objective response rate (9%). Given its unique mechanism and immune toxicity, real-world data are essential to understand its safety and feasibility in practice.

Fields of Study & Subjects

Ocular Oncology and Treatments Ocular Diseases and Behçet’s Syndrome Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100483–100483
Publication date
1 March 2026
Language
EN